Active Investments

Avalanche Biotech

Private

Juno Therapeutics

Private

BioCryst Pharmaceuticals

Public (NASDAQ: BCRX)

DBV Technologies

Public (NYSE: DBV)

Dyax

Public (NASDAQ: DYAX)

Keryx Biopharmaceuticals

Public (NASDAQ: KERX)

Neurocrine Biosciences

Public (NASDAQ: NBIX)

Ocera Therapeutics

Public (NASDAQ: OCRX)

Alumni Investments

Amarin Corporation

Public (NASDAQ: AMRN)

Ardea Biosciences

Acquired by AstraZeneca

Medivation

Public (NASDAQ: MDVN)

NPS Pharmaceuticals

Public (NASDAQ: NPSP)

Vanda Pharmaceuticals

Public (NASDAQ: VNDA)

YM Biosciences

Acquired by Gilead

Bong Koh Partner

Focus Areas: Biotechnology
Location: New York

Bong joined Venrock in 2011 and has been doing public and private investing since 2004. He did his medical training at Harvard’s Mass Eye & Ear Infirmary (ophthalmology), Stanford Hospital (internal medicine) and UCSF (pathology).

Bong earned his B.A. from Yale University, his M.D. from the University of California, San Francisco, and an M.B.A. from Harvard Business School.

Active Companies

Avalanche Biotech

Juno Therapeutics

BioCryst Pharmaceuticals

DBV Technologies

Dyax

Keryx Biopharmaceuticals

Neurocrine Biosciences

Ocera Therapeutics

Alumni Companies

Amarin Corporation

Ardea Biosciences

Medivation

NPS Pharmaceuticals

Vanda Pharmaceuticals

YM Biosciences